Weekly Topotecan for Recurrent Small Cell Lung Cancer - a Retrospective Anatolian Medical Oncology Group Study

Basit Öğe Kaydı
dc.contributor.authorAltinbas, Mustafa
dc.contributor.authorKalender, Mehmet Emin
dc.contributor.authorOven, Basak
dc.contributor.authorSevinc, Alper
dc.contributor.authorKaraca, Halit
dc.contributor.authorKaplan, M. Ali
dc.contributor.authorAlici, Suleyman
dc.date.accessioned2024-04-24T17:28:16Z
dc.date.available2024-04-24T17:28:16Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: To evaluate efficacy and tolerability of topotecan treatment for recurrent small cell lung carcinoma. Patients and Methods: A total of 62 patients were evaluated retrospectively. Statistical analysis was performed using GraphPad Instat (version 3.05). Results: DFifty five of patients (89%) were male and 7 (11%) were female. Median age was 56.7 +/- 9.3 (34-75). Forty eight of patients (80%) were extensive stage (ES) at the time of diagnosis. Fifty of the patients (80.6 Medical Oncology Clinic) were given median 5.36 cycles of cisplatin-etoposide (2-8 cycles). Time to recurrence was 15.6 +/- 6.13 weeks in patients with limited stage (LS) and 6.3 +/- 3.82 weeks in extensive stage (ES) (p<0.0001). Overall survival was 14.0 +/- 6.08 months in ES and 17.9 +/- 6.88 months in LS. The difference between two groups was statistically meaningful (p=0.0447). The overall survival of the patients was 14.8 +/- 6.43 months (4.5-40 months). In terms of survival, there was no difference between males and females (p=0.1171). In 17 (27%) patients who were refractory to topotecan or in whom progression occurred other chemotherapies were used. Conclusion: Small cell lung cancer is chemosensitive, but recurrences occur in short time. Other chemotherapy regimens are used in progression. Topotecan is one of them. Patients who were young and in whom recurrences occur late had given better response to topotecan. Because of the retrospective nature of the study, we couldn't reach the records exactly and consequently, rate and duration of response couldn't be calculated. In recurrent SCLC topotecan is one of the treatment choices. But both hematological and non hematological side effects should be taken into consideration.en_US
dc.identifier.doi10.7314/APJCP.2012.13.6.2909
dc.identifier.endpage2912en_US
dc.identifier.issn1513-7368
dc.identifier.issue6en_US
dc.identifier.pmid22938482
dc.identifier.scopus2-s2.0-84874064938
dc.identifier.scopusqualityQ3
dc.identifier.startpage2909en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2012.13.6.2909
dc.identifier.urihttps://hdl.handle.net/11468/20382
dc.identifier.volume13en_US
dc.identifier.wosWOS:000309472300084
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSmall Cell Lung Canceren_US
dc.subjectRecurrenceen_US
dc.subjectChemotherapyen_US
dc.subjectTopotecanen_US
dc.subjectToxicityen_US
dc.titleWeekly Topotecan for Recurrent Small Cell Lung Cancer - a Retrospective Anatolian Medical Oncology Group Studyen_US
dc.titleWeekly Topotecan for Recurrent Small Cell Lung Cancer - a Retrospective Anatolian Medical Oncology Group Study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu